ARFGAP2

Across TCGA pan-cancer cohorts, ARFGAP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARFGAP2 data layer compared with 18 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARFGAP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARFGAP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ARFGAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.881	0.617	.003	11	view →
HNSC	DFS	Median	III,IV	0.735	0.511	.016	8	view →
LUAD	DFS	Median	All	0.529	0.735	.024	7	view →
GBM	DFS	Median	All	0.489	0.261	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARFGAP2–PDAC (DFS)

Open the PDAC breakdown →